Increased serum prolactin pituitary reserve in patients with prostatic neoplasms.
Prolactin (PRL) pituitary reserve was measured in 8 patients with prostatic adenoma and 11 patients with prostatic carcinoma. The PRL reserve was significantly higher in these patients compared to an age-matched control group of 6 subjects. A possible role for PRL-inhibiting drugs in the management of oestrogen-resistant carcinomas of the prostate is suggested.